Condition: Acute Myeloid Leukemia, in Relapse · Acute Myeloid Leukemia Refractory · Sponsor: AvenCell Europe GmbH
The Allo-RevCAR01-T-CD123 drug is a combination of a cellular component (Allo-RevCAR01-T) with a recombinant antibody derivative (R-TM123), which together form the active drug. The cellular component Allo-RevCAR01-T consists of an allogeneic human T-cell genetically multi-edited and expressing a reversed, universal chimeric antigen receptor (RevCAR) presenting an extracellular peptide epitope (RevCAR epitope). R-TM123 functions as a bridging module between Allo-RevCAR01-T and a CD123-expressing target cancer cell by selectively binding the RevCAR epitope and CD123.
This description comes directly from the study's public registry record.
Katja Jersemann, Dr. · 0493514466450 · AVC-201-01@avencell.com
Martina Raupach · 0493514466450 · AVC-201-01@avencell.com
Always discuss trial participation with your own doctor first.
| Universitätsklinikum Ulm | Ulm, Baden-Wurttemberg, Germany | Recruiting |
| Klinikum der Universität München | Munich, Bavaria, Germany | Recruiting |
| Universitätsklinikum Würzburg | Würzburg, Bavaria, Germany | Recruiting |
| Universitätsklinikum Marburg | Marburg, Hesse, Germany | Recruiting |
| Universitätsklinikum Dresden | Dresden, Saxony, Germany | Recruiting |
| Charité Universitätsmedizin Berlin | Berlin, Germany | Recruiting |
| Universitätsklinikum Köln | Cologne, Germany | Recruiting |
| Medizinische Hochschule Hannover | Hanover, Germany | Recruiting |
| Erasmus University Medical Center | Rotterdam, Gelderland, Netherlands | Recruiting |
| Amsterdam University Medical Center | Amsterdam, HV, Netherlands | Not Yet Recruiting |
| University Medical Center Groningen (UMCG) | Groningen, RB Groningen, Netherlands | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05949125